Tests worth taking,
in the perimenopause window.

The honest reading of the literature: there is signal, and there is also a measurement-without-meaning problem. The Berry 2020 PREDICT 1 trial established that postprandial glucose responses to identical meals vary widely across UK adults, with person-specific factors carrying more weight than meal macronutrients for some markers. The Hall 2018 study showed adults considered normoglycemic by standard testing routinely show CGM excursions a consumer-facing app reads as red. The Bermingham 2022 ZOE PREDICT sub-analysis specifically reported less favourable post-meal glucose responses in post-menopausal versus pre-menopausal women in the same cohort — so the menopause-and-glucose question is real. The case for a CGM as a paid wellness device for a woman without diabetes is weaker than the marketing suggests; the case for a CGM as a research tool inside a programme like ZOE that pairs the data with nutritional context is stronger.

The Thigpen 2025 validation analysis on 1,155 cycles found the Oura physiology-based ovulation date detected 96.4% of ovulations with a mean error of 1.26 days, against 3.44 days for the calendar method — meaningfully more accurate than calendar tracking, and stable across age 18–52. The caveat for a perimenopausal reader: the value of cycle tracking declines as cycles become more variable and widely spaced through the menopausal transition. The Cunningham 2024 Flo cohort of 19 million users documents the age-related drift — cycles get shorter and more variable through the late reproductive stage and then longer and more variable through the menopausal transition. A wearable tracks what is there to track; in late perimenopause, what is there to track is less.

Symptom tracker apps are not diagnostic devices and are not regulated as such. What they are useful for is the same thing a paper diary would be useful for: a longitudinal record of which symptoms cluster, which days they cluster on, and what a GP consultation might benefit from being shown. The Balance app from Newson Health is the most-cited UK option, free at the point of use, and the research-context paper on its underlying data is the Bermingham 2022 ZOE PREDICT collaboration. The honest framing: a symptom tracker is a record-keeping tool to bring to a clinical conversation, not a substitute for one.

Because this is the page on the site where the answer is not a Solgar supplement. There is no supplement that diagnoses a hormone level, measures a glucose excursion, detects an ovulation date or logs a symptom — those are the jobs of tests, devices, wearables and apps. HerStack is published by Suggestic, a digital nutrition company; we picked Solgar UK as the reference brand for the supplement clusters where formulation matters. On this cluster, the criteria that matter are different — UK availability, regulatory status, the research base behind the measurement, and an honest framing of what the result tells you. The cards below are written against those criteria.

We review each cluster page against new evidence quarterly, and update the page header date when we make a substantive change. The service/device cards below carry their own last-reviewed date so you can see when the provider price ranges and the regulatory status were last checked.